Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

Nature Communications

Volumn 5, Issue , 2014, Pages

  Okell, Lucy C ^a   Cairns, Matthew ^b   Griffin, Jamie T ^a   Ferguson, Neil M ^a   Tarning, Joel ^c,d   Jagoe, George ^e   Hugo, Pierre ^e   Baker, Mark ^e   D'Alessandro, Umberto ^b,f,g   Bousema, Teun ^h   Ubben, David ^e   Ghani, Azra C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Switzerland   (Switzerland)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; BENFLUMETOL; DIHYDROARTEMISININ; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

COST-BENEFIT ANALYSIS; DISEASE TREATMENT; ESTIMATION METHOD; HEALTH CARE; HEALTH POLICY; MALARIA;

ADOLESCENT; ADULT; AFRICA; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MATHEMATICAL MODEL; NEWBORN; PARASITE TRANSMISSION; PLASMA CONCENTRATION-TIME CURVE; POPULATION DENSITY; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFECTION; SEASONAL VARIATION; SIMULATION; ECONOMICS; MALARIA, FALCIPARUM; SEASON; THEORETICAL MODEL;

AFRICA;

AFRICA; ANTIMALARIALS; ARTEMISININS; COST-BENEFIT ANALYSIS; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MODELS, THEORETICAL; QUINOLINES; SEASONS;

EID: 84923377601     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6606     Document Type: Article

References (61)

1. World Health Organization. WHO Guidelines for the Treatment of Malaria 2nd edn (WHO Press, 2010).
2. Smith, D. L., Klein, E. Y., McKenzie, F. E. & Laxminarayan, R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar. J. 9, 217 (2010).
3. The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 8, e1000402 (2011).
4. Okell, L. C., Drakeley, C. J., Bousema, T., Whitty, C. J. & Ghani, A. C. Modelling the impact of artemisinin combination therapy and long-Acting treatments on malaria transmission intensity. PLoS Med. 5, e226 (2008).
5. Cairns, M. et al. Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children. PLoS ONE 6, e18947 (2011).
6. Kumar, N. & Zheng, H. Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol. Res. 76, 214-218 (1990).
7. World Health Organization. World Malaria Report 2013 (2013).
8. Tarning, J. et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin. Pharmacol. Ther. 91, 497-505 (2012).
9. Pfeil, J., Borrmann, S. & Tozan, Y. Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis. PLoS ONE 9, e95681 (2014).
10. Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 8, e1001119 (2011).
11. Sawa, P. et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J. Infect. Dis. 207, 1637-1645 (2013).
12. van Pelt-Koops, J. C. et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56, 3544-3548 (2012).
13. Adjalley, S. H. et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl Acad. Sci. USA 108, E1214-E1223 (2011).
14. Bassat, Q. et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, noninferiority trial. PLoS ONE 4, e7871 (2009).
15. Zongo, I. et al. Randomized comparison of amodiaquine plus sulfadoxinepyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin. Infect. Dis. 45, 1453-1461 (2007).
16. Tarning, J. et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53, 3837-3846 (2009).
17. Griffin, J. T. et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 7, e1000324 (2010).
18. WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 10, e1001564 (2013).
19. Sinclair, D., Zani, B., Donegan, S., Olliaro, P. & Garner, P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. CD007483 (2009).
20. Griffin, J. T., Ferguson, N. M. & Ghani, A. C. Estimates of the changing ageburden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat. Commun. 5, 3136 (2014).
21. Bigira, V. et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young ugandan children: a randomized controlled trial. PLoS Med. 11, e1001689 (2014).
22. United Nations, Department of Economic & Social Affairs, Population Division. World Population Prospects, the 2010 Revision. Available at http://esa.un.org/wpp/, last accessed February 2013 (2010).
23. Oak Ridge National Laboratory. LandScan High Resolution Global Population Data Set. Available at http://www.ornl.gov/sci/landscan/(2011).
24. Gething, P. W. et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar. J. 10, 378 (2011).
25. Cairns, M. et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat. Commun. 3, 881 (2012).
26. Flaxman, A. D. et al. Rapid scaling up of insecticide-treated bed net coverage in Africa and its relationship with development assistance for health: a systematic synthesis of supply, distribution, and household survey data. PLoS Med. 7, e1000328 (2010).
27. Cohen, J. M. et al. Public health. Optimizing investments in malaria treatment and diagnosis. Science 338, 612-614 (2012).
28. World Health Organization. World Malaria Report 2012 (2012).
29. White, M. T., Conteh, L., Cibulskis, R. & Ghani, A. C. Costs and costeffectiveness of malaria control interventions-A systematic review. Malar. J. 10, 337 (2011).
30. Conteh, L. et al. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS ONE 5, e10313 (2010).
31. Conteh, L. et al. Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children. PLoS ONE 5, e12223 (2010).
32. Management Sciences for Health. International Drug Price Indicator Guide. Available at http://erc.msh.org (last accessed December 2012).
33. Dunyo, S. et al. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin. Trials 1, e20 (2006).
34. Okell, L. C., Drakeley, C. J., Ghani, A. C., Bousema, T. & Sutherland, C. J. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar. J. 7, 125 (2008).
35. Bousema, T. et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 9, 136 (2010).
36. White, N. J. How antimalarial drug resistance affects post-treatment prophylaxis. Malar. J. 7, 9 (2008).
37. Tran, T. H. et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363, 18-22 (2004).
38. Leang, R. et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 57, 818-826 (2013).
39. Amaratunga, C. et al. in American Society of Tropical Medicine & Hygiene. 62nd Annual Meeting. Symposium 44: Artemisinin-Resistant Plasmodium falciparum Malaria: Latest Findings from Clinical Molecular and Behavioral Studies (2013).
40. Hastings, I. M., Watkins, W. M. & White, N. J. The evolution of drug-resistant malaria: the role of drug elimination half-life. Phil. Trans. R. Soc. Lond. B. Biol. Sci. 357, 505-519 (2002).
41. Basco, L. K., Bickii, J. & Ringwald, P. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrob. Agents Chemother. 42, 2347-2351 (1998).
42. Denis, M. B. et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated Falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11, 1800-1807 (2006).
43. Song, J. et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar. J. 10, 231 (2011).
44. Mace, K. E. et al. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin. Infect. Dis. 53, 772-779 (2011).
45. Ashley, E. A. et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12, 195-200 (2007).
46. Tarning, J. et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob. Agents Chemother. 56, 1997-2007 (2012).
47. Djimde, A. A. et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 55, 3994-3999 (2011).
48. Lengeler, C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. CD000363 (2004).
49. Mueller, I. et al. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc. Natl Acad. Sci. USA 109, 10030-10035 (2012).
50. Hermsen, C. C. et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol. Biochem. Parasitol. 118, 247-251 (2001).
51. Ezzet, F., van Vugt, M., Nosten, F., Looareesuwan, S. & White, N. J. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44, 697-704 (2000).
52. Wanzira, H. et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisininpiperaquine for the treatment of malaria. Clin. Infect. Dis. 59, 509-516 (2014).
53. Measure-DHS. Demographic and Health Surveys. Available at http://www.measuredhs.com/.
54. Global Fund AMfM Summary report on Co-Payments. Available at http://www. theglobalfund.org/en/amfm/firstlinebuyers/reports/(last accessed July 2013).
55. WHO CHOICE. Country-specific unit costs. Available at http://www.who.int/choice/costs/en/(last accessed December 2012).
56. Tan-Torres Edejer, T. et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis (World Health Organization, 2003).
57. De Beaudrap, P. et al. Heterogeneous decrease in malaria prevalence in children over a six-year period in south-western Uganda. Malar. J. 10, 132 (2011).
58. Hay, S. I. et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med. 6, e1000048 (2009).
59. Zambia Ministry of Health. Zambia Malaria Indicator Survey 2006, Final Report. Available at http://www.nmcc.org.zm/files/2006-Zambia-Malaria- Indicator-Survey.pdf (2006).
60. Okell, L. C. et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE 6, e20179 (2011).
61. Chanda, P., Castillo-Riquelme, M. & Masiye, F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff. Resour. Alloc. 7, 5 (2009).